What’s the current market cap for Ingevity stock?

Ingevity (NGVT) has a market cap of $2.3B as of May 23, 2026.

What is the P/E ratio for Ingevity stock?

The price to earnings (P/E) ratio for Ingevity (NGVT) stock is 0 as of May 23, 2026.

Does Ingevity stock pay dividends?

No, Ingevity (NGVT) stock does not pay dividends to its shareholders as of May 23, 2026.

When is the next Ingevity dividend payment date?

Ingevity (NGVT) stock does not pay dividends to its shareholders.

What is the beta indicator for Ingevity?

Ingevity (NGVT) has a beta rating of 1.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Ingevity stock | $NGVT Share Price

13:30

15:10

16:45

18:25

20:00

About Ingevity

Ingevity Corp is a chemical manufacturer based in the United States. It conducts its operations through three segments, namely Performance Chemicals, Advanced Polymer Technologies, and Performance Materials. The bulk of its revenue is generated by the Performance Chemicals segment which deals with the manufacture and sale of specialty chemicals that find their use in a range of processes such as asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, and publication inks. The Performance Materials segment, on the other hand, focuses on automotive carbon products used in automobiles. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers. The company generates the majority of its revenue from North America.

Ticker

$NGVT

Sector

Materials

Primary listing

NYSE

Employees

1,500

Headquarters

North Charleston, United States

Website

www.ingevity.com

Ingevity Metrics

BasicAdvanced

$2.3bn

-$3.56

1.24

What the Analysts think about Ingevity

Analyst ratings (Buy, Hold, Sell) for Ingevity stock.

Bulls say / Bears say

Ingevity delivered $274 million in free cash flow in 2025—the best performance in five years—supporting debt repayments, share buybacks, and stronger liquidity (MarketBeat).

The company significantly strengthened its balance sheet by reducing net debt to adjusted EBITDA to 2.6 times by the end of 2025, down from 3.5 times the year before, improving financial flexibility (MarketBeat).

On January 1, 2026, Ingevity completed the sale of its North Charleston CTO refinery and most of its Industrial Specialties division for $110 million in cash (plus a possible additional $19 million), streamlining operations to focus on higher-margin specialty materials (BusinessWire).

Full-year 2025 sales dropped 8% year-over-year to about $1.3 billion, showing continued revenue pressure from repositioning efforts and weaker demand in major markets (MarketBeat).

In 2025, the company posted a GAAP net loss of $167 million, mainly due to a $184 million goodwill impairment in Advanced Polymer Technologies and a $109 million asset impairment in Road Markings, highlighting unpredictable profits in these lagging areas (MarketBeat).

Fourth-quarter 2025 revenue fell 7% year-over-year to $278 million, even though results were slightly ahead of expectations, pointing to persistent cyclical weakness in Performance Chemicals markets (Investing.com).

Data summarised monthly by Lightyear AI. Last updated on 28 Apr 2026.

Ingevity Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Ingevity Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NGVT

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

Ingevity delivered $274 million in free cash flow in 2025—the best performance in five years—supporting debt repayments, share buybacks, and stronger liquidity (MarketBeat).

Full-year 2025 sales dropped 8% year-over-year to about $1.3 billion, showing continued revenue pressure from repositioning efforts and weaker demand in major markets (MarketBeat).

Data summarised monthly by Lightyear AI. Last updated on 28 Apr 2026.